MDA Ltd. (MDA.TO)
CAD 28.15
(-1.81%)
CAD 28.15
(-1.81%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 807.6 Million | 641.2 Million | 476.9 Million | 295.6 Million |
| Cost of Revenue | 610.1 Million | 412.8 Million | 309.1 Million | 261.8 Million |
| Gross Profit | 197.5 Million | 228.4 Million | 167.8 Million | 33.8 Million |
| Operating Expenses | 198.1 Million | 153.8 Million | 124.4 Million | 74.2 Million |
| Selling, General and Administrative Expenses | 80.7 Million | 68.5 Million | 71.8 Million | 55.2 Million |
| Research and Development Expenses | 39.3 Million | 32.8 Million | 21.1 Million | 19 Million |
| Other Expenses | - | 52.5 Million | 31.5 Million | - |
| Cost and Expenses | 730.1 Million | 566.6 Million | 433.5 Million | 336 Million |
| Operating Income | 77.5 Million | 74.6 Million | 44.2 Million | -40.4 Million |
| Interest Expense | 8.6 Million | 34.2 Million | 32.2 Million | 29.4 Million |
| Income Tax Expense | 18.5 Million | 7.9 Million | 8.4 Million | -26.8 Million |
| Earnings before Tax | 67.3 Million | 34.2 Million | 11.3 Million | -44.1 Million |
| Net Income | 48.8 Million | 26.3 Million | 2.9 Million | -17.3 Million |
| Earnings Per Share Basic | 0.41 | 0.22 | 0.02 | -0.15 |
| Earnings Per Share Diluted | 0.40 | 0.21 | 0.02 | -0.15 |
| Weighted Average Shares Outstanding | 119.25 Million | 119.01 Million | 118.69 Million | 117.77 Million |
| Weighted Average Shares Outstanding (Diluted) | 121.17 Million | 122.45 Million | 118.69 Million | 117.77 Million |
| Gross Margin | 0.24 | 0.36 | 0.35 | 0.11 |
| EBIT Margin | 0.15 | 0.24 | 0.26 | 0.06 |
| Profit Margin | 0.06 | 0.04 | 0.01 | -0.06 |
| EBITDA | 121.7 Million | 150.8 Million | 124 Million | 43.6 Million |
| Earnings Before Tax Margin | 0.10 | 0.12 | 0.09 | -0.14 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 242 Million | 209.1 Million | 807.6 Million | 205 Million | 204.7 Million | 196 Million |
| Cost of Revenue | 187.4 Million | 163.5 Million | 610.1 Million | 158.9 Million | 147 Million | 134.7 Million |
| Gross Profit | 54.6 Million | 45.6 Million | 197.5 Million | 46.1 Million | 57.7 Million | 61.3 Million |
| Operating Expenses | 43.4 Million | 38.5 Million | 152.3 Million | 44.4 Million | 42 Million | 42 Million |
| Selling, General and Administrative Expenses | 23.7 Million | 21.4 Million | - | 21.6 Million | 20.6 Million | 20.7 Million |
| Research and Development Expenses | 19.7 Million | 17.1 Million | - | 22.8 Million | 10.4 Million | 10.3 Million |
| Other Expenses | 100 Thousand | 6.5 Million | - | - | - | - |
| Cost and Expenses | 230.8 Million | 202 Million | 762.4 Million | 203.3 Million | 189 Million | 176.7 Million |
| Operating Income | 11.2 Million | 7.1 Million | 45.2 Million | 1.7 Million | 15.7 Million | 19.3 Million |
| Interest Expense | 7.9 Million | 6.1 Million | 17.5 Million | 3.7 Million | 2.4 Million | 2.1 Million |
| Income Tax Expense | -7.4 Million | -2.4 Million | -13.8 Million | -14.4 Million | 5.6 Million | 4.9 Million |
| Earnings before Tax | 3.6 Million | 11.4 Million | 35 Million | -900 Thousand | 14.9 Million | 14.8 Million |
| Net Income | 11 Million | 13.8 Million | 48.8 Million | 13.5 Million | 9.3 Million | 9.9 Million |
| Earnings Per Share Basic | 0.09 | 0.12 | - | 0.11 | 0.08 | 0.08 |
| Earnings Per Share Diluted | 0.09 | 0.11 | - | 0.11 | 0.08 | 0.08 |
| Weighted Average Shares Outstanding | 120.05 Million | 119.58 Million | 119.25 Million | 119.51 Million | 119.32 Million | 119.16 Million |
| Weighted Average Shares Outstanding (Diluted) | 123.51 Million | 123.26 Million | 121.17 Million | 122.69 Million | 121.91 Million | 120.25 Million |
| Gross Margin | 0.23 | 0.22 | 0.24 | 0.22 | 0.28 | 0.31 |
| EBIT Margin | 0.14 | 0.14 | - | 0.11 | 0.17 | 0.19 |
| Profit Margin | 0.05 | 0.07 | 0.06 | 0.07 | 0.05 | 0.05 |
| EBITDA | 33.7 Million | 29.9 Million | - | 22.6 Million | 35.5 Million | 37.3 Million |
| Earnings Before Tax Margin | 0.05 | 0.03 | 0.06 | 0.01 | 0.08 | 0.10 |
RATNAMANI
4623
6113
PCAT
2923
ASB